Outcome/risk score | Overall | Females | Males |
30-day mortality | 11.5% (n=703) | 12.2% (n=312) | 11.0% (n=391) |
GWTG-HF (n=300) | |||
Tertile 1 | 7.2% (n=97) | 9.4% (n=53) | 4.5% (n=44) |
Tertile 2 | 6.1% (n=99) | 6.1% (n=49) | 6.0% (n=50) |
Tertile 3 | 23.1% (n=104) | 22.5% (n=40) | 23.4% (n=64) |
p-trend* | <0.001 | 0.08 | 0.002 |
30-day IMRS | |||
Low risk | 4.6% (n=217) | 2.5% (n=79) | 5.8% (n=138) |
Moderate risk | 11.0% (n=310) | 13.3% (n=158) | 8.6% (n=152) |
High risk | 21.0% (n=176) | 20.0% (n=75) | 21.8% (n=101) |
p-trend* | <0.001 | <0.001 | <0.001 |
1-year mortality | 30.3% (n=703) | 32.1% (n=312) | 28.9% (n=391) |
GWTG-HF (n=300) | |||
Tertile 1 | 16.5% (n=97) | 20.8% (n=53) | 11.4% (n=44) |
Tertile 2 | 23.2% (n=99) | 22.4% (n=49) | 24.0% (n=50) |
Tertile 3 | 37.5% (n=104) | 35.0% (n=40) | 39.1% (n=64) |
p-trend* | <0.001 | 0.13 | 0.001 |
1-year IMRS | |||
Low risk | 7.4% (n=68) | 5.6% (n=18) | 8.0% (n=50) |
Moderate risk | 25.2% (n=353) | 25.8% (n=132) | 24.9% (n=221) |
High risk | 42.2% (n=282) | 40.1% (n=162) | 45.0% (n=120) |
p-trend* | <0.001 | <0.001 | <0.001 |
For GWTG-HF, tertiles constituted patients with scores of ≤37 (tertile 1), 38–45 (tertile 2), and ≥46 (tertile 3). For IMRS, 30-day risk categories for females and males were, respectively, low-risk: ≤14 and≤14; moderate risk: 15–19 and 15–18; high risk: ≥20 and≥19; while 1-year risk categories for females and males were, respectively, low risk: ≤8 and ≤10; moderate risk: 9–14 and 11–16; high risk: ≥15 and ≥17.
*P-trend across tertiles 1, 2, and 3 of GWTG-HF or across low, moderate, and high-risk categories of IMRS.
IMRS, Intermountain Mortality Risk Score.